The Korean Journal of Nuclear Medicine (대한핵의학회지)

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

Clinical Application of PET in Abdominal Cancers

소화기 암에서 PET의 임상적 의의

  • Published : 2002.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Clinical application of positron emission tomography (PET) is rapidly increasing for the defection and staging of cancer at whole-body studios performed with the glucose analogue tracer 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG). Although FDG PET cannot match the anatomic resolution of conventional imaging techniques in the liver and the other abdominal organs, it is particularly useful for identification and characterization of the entire body simultaneously. FDG PET can show foci of metastatic disease that may not be apparent at conventional anatomic imaging and can aid in the characterizing of indeterminate soft-tissue masses. Most abdominal cancer requires surgical management. FDG PET can improve the selection of patients for surgical treatment and thereby reduce the morbidity and mortality associated with inappropriate surgery. FDG PET is also useful for the early detection of recurrence and the monitoring of therapeutic effect. The abdominal cancers, such as gastroesophageal cancer, colorectal cancer, liver cancer and pancreatic cancer, are common malignancies in Korea, and PET is one of the most promising and useful methodologies for the management of abdominal cancers.

Keywords

References

  1. 고창순(1997) : 핵의학, 제2판, 고려의학, 서울.
  2. Khalkhali I, Maublant JC, Goldsmith SJ. NuclearOncology. 1st ed. Philadelphia, Lippincott Williams& Wilkins, 2001.
  3. Delbeke D, Martin WHo Positron emissiontomography imaging in oncology. Radiol ClinNorth Am 2001;39:883-917.
  4. Mankoff DA, Bellon JR. Positron-emissiontomographic imaging of cancer: glucose metabolismand beyond. Semin Radiat Oncol 2001;11:16-27.
  5. Anderson H, Price P. What does positron emissiontomography offer oncology? Eur J Cancer 2000;36:2028-35.
  6. Delbeke D, Martin WH, Sandler MP, ChapmanWC, Wright JK Jr, Pinson CWo Evaluation ofbenign vs malignant hepatic lesions with positronemission tomography. Arch Surg 1998;133:510-15.
  7. Goldberg MA, Lee MJ, Fischman AI, Mueller PR,Alpert NM, Thrall JH. Fluorodeoxyglucose PETof abdominal and pelvic neoplasms: potential rolein oncologic imaging. Radiographies 1993;13:1047-62.
  8. Trojan J, Schroeder 0, Raedle J, Baum RP,Herrmann G, Jacobi V, et al. Fluorine-18 FDGpositron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 1999;94:3314-19.
  9. Yasuda S, Makuuchi Y, Sadahiro S, Mukai M,Tokunaga N, Tajima T, et al. Colorectal cancerrecurrence in the liver: detection by PET. Tokai JExp Clin Med 1998;23:167-171.
  10. Frolich A, Diederichs CG, Staib L, et al.Detection of liver metastasis from pancreatic cancerusing FDG PET. J Nucl Med 1999;40:250-55.
  11. 한철주. 각종 간종양에서 PET 영상의 비교. 원자력병원 2000년도 자체연구개발사업 보고서.
  12. Lai DT, Fulham M, Stephen MS, Chu KM,Solomon M, Thompson JF, et al. The role ofwhole-body positron emission tomography with[18F]fluorodeoxyglucose in identifying operablecolorectal cancer metastases to the liver. Arch Surg1996;131:703-7.
  13. Delbeke D, Vitola JV, Sandler MP, Arildsen RC,Powers TA, Wright JK Jr, et al. Staging recurrentmetastatic colorectal carcinoma with PET. J Nucl Med 1997;38:1196-201.
  14. Moertel CG, Fleming TR, Macdonald JS, HallerDG, Laurie JA, Tangen C. An evaluation of thecarcinoembryonic antigen (CEA) test formonitoring patients with resected colon cancer.JAMA 1993;25;270:943-7.
  15. Chen YM, Ott OJ, Wolfman NT, Gelfand DW,Karsteadt N, Bechtold RE. Recurrent colorectalcarcinoma: evaluation with barium enemaexamination and CT. Radiology 1987;163:307-10.
  16. Valk PE, Abella-Columna E, Haseman MK, PoundsTR, Tesar RD, Myers RW, et al. Whole-body PETimaging with [18F]fluorodeoxyglucose in managementof recurrent colorectal cancer. Arch Surg1999;134:503-11.
  17. Kuntz C, Herefarth C. Imaging diagnosis forstaging of gastric cancer. Semin in Surg Oncol1999;17:96-102.
  18. Ziegler K, Sanft C, Zimmer T, et al. Comparisonof computed tomography, endosonography andintraoperative assessment in TN staging of gastriccarcinoma. Gut 1993;34:604-10.
  19. Halvorsen RA Jr, Yee J, McConnick VD.Diagnosis and staging of gastric cancer. SeminOncol 1996;23:325-35.
  20. Sohn KM, Lee JM, Lee SY, Ahn BY, Park SM,Kim KM. Comparing MR imaging and CT in thestaging of gastric carcinoma. ARJ 2000;174:1551-57.
  21. Kim AY, Han JK, Seong CK, Kim TK, Choi BI.MRI in staging advanced gastric cancer: Is it usefulcompared with spiral CT? J Comput Assist Tomogr2000;24:389-94.
  22. Kim BI, Lee II, Yang WI, Lee JS, Cheon GJ, ChoiCW, et al. Findings of F-18 FDG whole body PETin patients with stomach cancer. Korean J NuclMed 2001;35:301-12.
  23. Nunez RF, Yeung HW, Macapinlac H. IncreasedF-18 FDG uptake in the stomach. Clin Nucl Med1999;24:281-82.
  24. Kato T, Tsukamoto E, Suginami Y, Mabuchi M,Yoshinaga K, Tokano A, et al. Visualization ofnormal organs in whole-body FDG-PET imaging.Kaku Igaku 1999;36:971-7.
  25. Gary JR. Cook, Michael N. Maisey, IgnacFogelman. Normal variants, artefacts andinterpretative pitfalls in PET imaging with18-fluoro-2-deoxyglucose and carbon-ll methionine.Eur J Nucl Med 1999;26;1363-78.
  26. Choi JY, Lee KH, Shim YM, Lee KS, Kim JJ,Kim SE, et al. Improved detection of individualnodal involvement in squamous cell carcinoma ofthe esophagus by FDG PET. J Nucl Med2000;41:808-15.
  27. Keogan MT, Tyler D, Clark L, Branch MS,McDennott VG, DeLong DM, et al. Diagnosis ofpancreatic carcinoma: role of FDG PET. Am JRoentgenol 1998 ;171:1565-70.
  28. Bares R, Klever P, Hauptmann S, Hellwig D, FassJ, Cremerius U, Schumpelick V, Mittennayer C,Bull U. F-18 fluorodeoxyglucose PET in vivoevaluation of pancreatic glucose metabolism fordetection of pancreatic cancer. Radiology1994;192:79-86.
  29. Nakata B, Chung YS, Nishimura S, Nishihara T,Sakurai Y, Sawada T, et aI. 18F-fluorodeoxyglucosepositron emission tomography and the prognosis ofpatients with pancreatic adenocarcinoma. Cancer1997;15;79:695-9.